WALTHAM, MA • 2022-10-04

BostonGene Announces Publication in Cell Reports Revealing Spatial Heterogeneity in the Tumor Microenvironment of Multiregional Clear Cell Renal Cell Carcinoma Biopsies

5 min to read

Study finds that tumor microenvironment-expressed cytokines impact treatment response of clear cell renal cell carcinoma patients
WALTHAM, MA – October 4, 2022

BostonGene Corporation announced the online publication of the manuscript, “Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity” in Cell Reports, a peer-reviewed open access journal that publishes high-quality scientific research and new biological insights across the entire life sciences spectrum. The study, conducted in collaboration with researchers at Washington University School of Medicine in St. Louis, revealed that intratumor spatial heterogeneity (ITH) occurs in clear cell renal cell carcinoma (ccRCC), which may drive clinical heterogeneity and warrants further investigation to improve patient outcomes.

Multiregional analyses revealed unexpected conservation of immune composition of the tumor microenvironment (TME) within each patient, with profound differences found among patients. Despite genetic heterogeneity from clonal evolution, patient-specific immune TME signatures were identified and confirmed by MxIF cell phenotyping and BostonGene’s RNA-seq deconvolution algorithm, Kassandra.  Further MxIF analysis showed striking spatial architectural heterogeneity among different regions of the same tumor, revealing the presence of diverse cellular neighborhoods.

By coupling experimental tools, including multiomic profiling and multiplex imaging, with artificial intelligence-driven analytics, we dissected the complex tumor ecosystem at different hierarchical levels, providing insights into both ITH and clinical heterogeneity in ccRCC.

“The research conducted with Washington University underscores the importance of implementing a multifaceted approach to understanding tumor biology and the tumor ecosystem as a way to promote better clinical outcomes in ccRCC patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene. “We believe these integrated methods to identify biomarkers of response to therapies will ultimately help to improve precision medicine strategies for these patients.”

“This study was designed to characterize the role of the tumor microenvironment in ccRCC using multiomic analyses,” said James Hsieh, MD, PhD, a medical oncologist and Professor of Medicine at Washington University School of Medicine in St Louis. “The findings indicated tumor behavior specificities linked with patient responses, and the MxIF analyses identified 14 unique cellular neighborhoods in multi-region tumors that can be utilized to optimize treatment strategies for patients with ccRCC.”

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s service model provides customized client solutions using a multi-omic approach prioritized for real-world impact, including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Erin O’Reilly

Senior Director